Foamix Pharmaceuticals (FOMX) Rating Lowered to Sell at Zacks Investment Research
Foamix Pharmaceuticals (NASDAQ:FOMX) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report issued on Thursday.
According to Zacks, “Foamix Pharmaceuticals Ltd. is a specialty pharmaceutical company. It develops and commercializes foam-based formulations acne, impetigo, and other skin conditions. The Company’s lead product candidates include FMX101, which has completed a dose-ranging Phase II clinical trial for the treatment of moderate-to-severe acne; and FMX102 that has completed a Phase II clinical trial for the treatment of impetigo. It has operations primarily in the United States, Germany, and Israel. Foamix Pharmaceuticals Ltd. is headquartered in Rehovot, Israel. “
Other research analysts have also recently issued reports about the stock. Guggenheim began coverage on shares of Foamix Pharmaceuticals in a research report on Tuesday, December 5th. They set a “buy” rating and a $8.00 price target on the stock. HC Wainwright set a $12.00 price target on shares of Foamix Pharmaceuticals and gave the company a “buy” rating in a research report on Friday, January 5th.
In other Foamix Pharmaceuticals news, insider Meir Eini sold 5,000 shares of the stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $6.18, for a total transaction of $30,900.00. Following the transaction, the insider now directly owns 16,271 shares in the company, valued at $100,554.78. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have sold 20,000 shares of company stock worth $125,400 over the last quarter.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. Handelsbanken Fonder AB grew its position in Foamix Pharmaceuticals by 58.8% during the fourth quarter. Handelsbanken Fonder AB now owns 270,000 shares of the specialty pharmaceutical company’s stock valued at $1,623,000 after acquiring an additional 100,000 shares during the last quarter. Millennium Management LLC grew its position in Foamix Pharmaceuticals by 4.8% during the fourth quarter. Millennium Management LLC now owns 743,668 shares of the specialty pharmaceutical company’s stock valued at $4,469,000 after acquiring an additional 33,893 shares during the last quarter. Driehaus Capital Management LLC grew its holdings in shares of Foamix Pharmaceuticals by 3.1% in the fourth quarter. Driehaus Capital Management LLC now owns 548,042 shares of the specialty pharmaceutical company’s stock worth $3,294,000 after purchasing an additional 16,475 shares during the last quarter. AXA grew its holdings in shares of Foamix Pharmaceuticals by 1.0% in the fourth quarter. AXA now owns 952,554 shares of the specialty pharmaceutical company’s stock worth $5,725,000 after purchasing an additional 9,819 shares during the last quarter. Finally, Ascend Capital LLC grew its holdings in shares of Foamix Pharmaceuticals by 42.0% in the fourth quarter. Ascend Capital LLC now owns 566,829 shares of the specialty pharmaceutical company’s stock worth $3,408,000 after purchasing an additional 167,643 shares during the last quarter. Institutional investors and hedge funds own 56.59% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Foamix Pharmaceuticals (FOMX) Rating Lowered to Sell at Zacks Investment Research” was originally posted by Watch List News and is the property of of Watch List News. If you are reading this article on another domain, it was illegally copied and republished in violation of United States and international copyright law. The legal version of this article can be accessed at https://www.watchlistnews.com/foamix-pharmaceuticals-fomx-rating-lowered-to-sell-at-zacks-investment-research/1903350.html.
About Foamix Pharmaceuticals
Foamix Pharmaceuticals Ltd. is a clinical-stage pharmaceutical company. The Company is engaged in the development and commercialization of foam-based formulations, using its technology, which includes its foam platforms. It is focused on developing and commercializing its minocycline foam for the treatment of acne, rosacea and other skin conditions.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Foamix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foamix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.